Edit |   |
---|---|
Antigenic Specificity | IL17A, Human (Bimekizumab biosimilar) |
Clone | Bimekizumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | ELISA, FCM, IP, FuncS, IF, Neut |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human IL17A Recombinant Antibody (Bimekizumab). Bimekizumab (INN) is a humanized anti-IL17A and IL-17F monoclonal antibody that is being investigated for ankylosing spondylitis, psoriatic arthritis, and psoriasis. This drug is being developed by Belgian pharmaceutical UCB. As of 2018, bimekizumab is undergoing Phase III trials. |
Immunogen | n/a |
Other Names | Anti-IL17A Recombinant Antibody, Research Grade Bimekizumab, Anti-Human IL17A Recombinant Antibody(Bimekizumab), CDP4940, Antibody Drug Analogues, Monoclonal Antibody, YR1328, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1418205-77-2 |
Catalog # | YR1328 |
Price | please inquire |
Order / More Info | IL17A, Human (Bimekizumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |